Out-Licensing Imidafenacin to Spain
First written in FY2019-Q1. 2 of 3 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019RestatedAnnual report
「Imidafenacin Faes Farma Spain Consideration: upfront fee, development milestones, sales milestones Contract year: 2018 Contract term: 10 years from the launch date (automatic renewal)」
The company continues to disclose the out-licensing agreement for imidafenacin with Faes Farma in Spain. - FY2019-Q2RestatedAnnual report
「Out-licensing to a foreign company; product: imidafenacin; Faes Farma; Spain; consideration: upfront fee, development milestones and sales milestones; contract year: 2018; term: 10 years from launch, automatically renewable.」
The company continues to disclose the out-licensing agreement for imidafenacin with Faes Farma in Spain. - FY2019-Q1First statedAnnual report
「Out-licensing to a foreign company; product: imidafenacin; Faes Farma; Spain; consideration: upfront fee, development milestones and sales milestones; contract year: 2018; term: 10 years from launch, automatically renewable.」
An out-licensing agreement for imidafenacin was newly signed with Spain’s Faes Farma, with upfront, development-milestone and sales-milestone payments.